MediciNova’s MN-001 trial misses primary endpoints in NAFLD

MediciNova, Inc. (MNOV) reported that its Phase 2 trial of MN-001 in NAFLD with hypertriglyceridemia showed some signals but missed primary endpoints. HDL-C, HDL-P improved, and early triglyceride reduction was significant. The company expects topline results for MN-166 in ALS by year-end.

MediciNova (MNOV) reported Phase 2 trial results for MN-001 in treating nonalcoholic fatty liver disease and hypertriglyceridemia. While primary endpoints were not met, significant improvements in HDL-C and HDL-P were observed. MN-001 was well-tolerated. The company plans further analysis and will assess next steps. Additionally, MediciNova is on track to report topline results for its Phase 2b/3 trial of MN-166 in ALS by year-end.

MediciNova Inc (MNOV) shares dropped 14.7% premarket after its Phase 2 trial for MN-001 in nonalcoholic fatty liver disease and hypertriglyceridemia missed primary endpoints at 24 weeks. While MN-001 showed early triglyceride reduction, the effect wasn't sustained. HDL cholesterol and particle concentration improvements were statistically significant. The company plans to assess next steps for development.

MediciNova Inc's stock fell 8.9% in pre-market trading after its Phase 2 trial data showed mixed results, failing to meet co-primary endpoints at 24 weeks. The trial tested MN-001 for NAFLD and hypertriglyceridemia in type 2 diabetes patients. The decline is exacerbated by a broader market downturn, with the Nasdaq and S&P 500 also down.

MediciNova Inc (MNOV) shares dropped 14.7% premarket after mixed Phase 2 trial results for tipelukast (MN-001) in treating NAFLD and hypertriglyceridemia. While the drug showed improvements in HDL cholesterol and particle concentration, key metrics like triglyceride reduction and liver fat changes were not statistically significant. The company plans further analysis and future study assessments.

Goldman Sachs upgraded CoreWeave (CRWV) to Buy, cutting its price target to $106. The AI cloud company's shares fell 25% last week amid debt concerns, despite $2.58B revenue and $104B backlog in Q2. Nvidia CEO defended CoreWeave, noting its improving strength and no financial backstop need.